<DOC>
	<DOCNO>NCT00537771</DOCNO>
	<brief_summary>The primary objective compare ARIMIDEX ( anastrozole ) 1 mg daily Tamoxifen 20 mg daily adjuvant treatment term : incidence fatty liver disease . The second objective compare ARIMIDEX ( anastrozole ) 1 mg daily Tamoxifen 20 mg daily adjuvant treatment term : incidence abnormal liver function test , time treatment failure .</brief_summary>
	<brief_title>Liver Safety Under Upfront Arimidex v Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically proven HR+ invasive breast cancer Completed primary surgery chemotherapy ( give ) , candidate receive hormonal adjuvant therapy Postmenopausal woman clinical evidence metastatic disease previous adjuvant hormonal therapy breast cancer liver disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Early Breast cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>hormone receptor</keyword>
	<keyword>hormonal therapy</keyword>
	<keyword>anastrozole</keyword>
	<keyword>tamoxifen</keyword>
</DOC>